v3.26.1
Financial Highlights (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
Per share data:      
Net asset value at beginning of period $ 17.23 $ 17.65  
Net investment income [1] 0.42 0.5  
Net realized loss [1],[2] (0.19) (0.41)  
Net change in unrealized appreciation [1],[3],[4] (0.18) 0.35  
Net increase in net assets resulting from operations [1],[5],[6] 0.05 0.44  
Stockholder distributions from income [7] (0.42) (0.45)  
Net asset value at end of period $ 16.86 $ 17.64  
Net assets at end of period | $ $ 1,093,555 $ 1,144,504 $ 1,117,410
Shares outstanding at end of period | shares 64,868,507 64,868,507  
Per share market value at end of period $ 12.4 $ 16.6  
Total return based on market value [8] (7.84%) (2.68%)  
Total return based on net asset value [9] 0.30% 2.51%  
Ratios:      
Ratio of net investment income to average net assets [10],[11] 11.72% 12.29%  
Ratio of total expenses to average net assets [10],[11] 12.30% 11.45%  
Supplemental data:      
Ratio of interest and debt financing expenses to average net assets [10],[11] 7.35 6.72  
Ratio of expenses (without incentive fees) to average net assets [10],[11] 11.80% 11.26%  
Ratio of incentive fees and management fees, net of contractual and voluntary waivers, to average net assets [10],[11] 3.80% 3.42%  
Average principal debt outstanding | $ $ 1,560,467 $ 1,437,769  
Portfolio turnover [12] 9.47% 10.06%  
Share Price At Initial Public Offering $ 12.4 $ 16.6  
[1] The per share data was derived by using the weighted average shares outstanding during the period.
[2] Net realized gain (loss) includes net realized gain (loss) on investments, net realized gain (loss) on forward currency exchange contracts, net realized gain (loss) on foreign currency transactions, and net realized gain (loss) on extinguishment of debt.
[3] Net change in unrealized appreciation includes net change in unrealized appreciation (depreciation) on investments, net change in unrealized appreciation on forward currency exchange contracts and net change in unrealized appreciation on foreign currency translation.
[4] Net change in unrealized appreciation on investments per share may not be consistent with the Consolidated Statements of Operations due to the timing of stockholder transactions.
[5] Net increase in net assets resulting from operations per share in these financial highlights may be different from the net increase (decrease) in net assets per share on the Consolidated Statements of Operations due to changes in the number of weighted average shares outstanding and the effects of rounding.
[6] The sum of quarterly per share amounts presented in previously filed financial statements on Form 10‑Q may not equal earnings per share. This is due to changes in the number of weighted average shares outstanding and the effects of rounding.
[7] The per share data for distributions reflects the actual amount of distributions declared during the period.
[8] Total return based on market value is calculated as the change in market value per share during the period, assuming dividends and distributions, plus the declared distributions, divided by the beginning market price for the period. Total return does not include upfront sales load and has not been annualized
[9] Total return based on net asset value is calculated as the change in net asset value per share during the period, assuming dividends and distributions, including those distributions that have been declared. Total return does not include upfront sales load and has not been annualized.
[10] Ratio is annualized. Incentive fees and income tax expense, including excise tax, if any, included within the ratio are not annualized.
[11] The computation of average net assets during the period is based on averaging net assets for the periods reported.
[12] Portfolio turnover rate is calculated using the lesser of year-to-date sales or year-to-date purchases over the average of the invested assets at fair value for the periods reported.